Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences
| Autor: | Avramopoulos Dimitri, Constantine G. Lyketsos, Peter V. Rabins, Lea T. Drye, Cynthia A. Munro, Matthew E. Peters, Vijay Vaidya, Curtis L. Meinert, Constantine Frangakis, Paul B. Rosenberg, Anton P. Porsteinsson, Lon S. Schneider, Jacobo Mintzer, Barbara K. Martin, Daniel Weintraub |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Oncology medicine.medical_specialty Genotype Article law.invention Randomized controlled trial Alzheimer Disease law Sertraline Internal medicine medicine Humans Multicenter Studies as Topic Dementia Psychiatry Serotonin Uptake Inhibitors Depression (differential diagnoses) Aged Randomized Controlled Trials as Topic Aged 80 and over Polymorphism Genetic Depression Middle Aged medicine.disease Psychiatry and Mental health Treatment Outcome Depression of Alzheimer disease Antidepressant Female Neurology (clinical) Geriatrics and Gerontology Alzheimer's disease Psychology Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | Journal of Geriatric Psychiatry and Neurology. 24:222-228 |
| ISSN: | 1552-5708 0891-9887 |
| DOI: | 10.1177/0891988711422527 |
| Popis: | Objective. To assess the potential for genetic influences on sertraline treatment efficacy for depression of Alzheimer disease (dAD). Four functional genetic variants were studied: 2 serotonin receptors (HTR2A-T102C and HTR2C-Cys23Ser), the serotonin transporter (5HTT-LPR), and brain-derived neurotrophic factor (BDNF-Val66Met). Treatment response by genotype was measured by (1) the modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change, (2) the Cornell scale for Depression in Dementia, and (3) remission of depression. Methods. We utilized data from the Depression in Alzheimer’s Disease Study 2 (DIADS-2), a 24-week, randomized, multicenter trial showing no significant treatment effect of sertraline on dAD. Proportional odds logistic regression and mixed effects models were used to examine the above mentioned outcome measures. Results. No significant interactions were seen between any of the genetic polymorphisms and the selected outcomes above at 12 or 24 weeks. Discussion. Treatment outcomes in the DIADS-2 trial were not significantly influenced by genetic variation at the loci that were assessed. Future studies should continue to examine the interaction of depression-related genetic variants with antidepressant treatment in Alzheimer disease patients with depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|